Your browser doesn't support javascript.
Would New SARS-CoV-2 Variants Change the War against COVID-19?
Redwan, Elrashdy M; Elrashdy, Fatma; Aljabali, Alaa A A; Baetas-da-Cruz, Wagner; Barh, Debmalya; Brufsky, Adam M; Hassan, Sk Sarif; Lundstrom, Kenneth; Serrano-Aroca, Ángel; Takayama, Kazuo; Tambuwala, Murtaza M; Uhal, Bruce D; Uversky, Vladimir N.
  • Redwan EM; Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.
  • Elrashdy F; Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, New Borg El-Arab, Alexandria 21934, Egypt.
  • Aljabali AAA; Department of Endemic Medicine and Hepatogastroenterology, Cairo University, Cairo 12111, Egypt.
  • Baetas-da-Cruz W; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 566, Jordan.
  • Barh D; Translational Laboratory in Molecular Physiology, Centre for Experimental Surgery, College of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-901, RJ, Brazil.
  • Brufsky AM; Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur 721172, West Bengal, India.
  • Hassan SS; Laboratório de Genética Celular e Molecular, Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
  • Lundstrom K; UPMC Hillman Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
  • Serrano-Aroca Á; Department of Mathematics, Pingla Thana Mahavidyalaya, Maligram, Paschim Medinipur 721140, West Bengal, India.
  • Takayama K; PanTherapeutics, Rte de Lavaux 49, CH 1095 Lutry, Switzerland.
  • Tambuwala MM; Biomaterials and Bioengineering Lab, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.
  • Uhal BD; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
  • Uversky VN; School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine BT52 1SA, UK.
Epidemiologia (Basel) ; 3(2): 229-237, 2022 Apr 29.
Article in English | MEDLINE | ID: covidwho-1820216
ABSTRACT
The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike protein the only vaccine target or is a vaccine cocktail better?
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Epidemiologia (Basel) Year: 2022 Document Type: Article Affiliation country: Epidemiologia3020018

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Epidemiologia (Basel) Year: 2022 Document Type: Article Affiliation country: Epidemiologia3020018